ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INBX / insiders
IMTX (44) CGEM (32) VOR (42) ODTX (46) ⌘ Pro Terminal →

Inhibrx Biosciences Inc. (INBX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$72.16 +0.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $72.09

Inhibrx Biosciences Inc. (INBX) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.06B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INBX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Inhibrx Biosciences Inc. (NASDAQ: INBX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $72.16 (+0.53% 1D, market cap $1.06B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, INBX ranks #995 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INBX compare to IMTX and CGEM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INBX carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $967.3M). Among the 5-stock peer group, INBX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INBX?
▼

Per INBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002007919), Inhibrx Biosciences Inc. generated $1.3M in revenue (+550.0% YoY), -$140.1M in net income, and -$129.8M in free cash flow against $146.5M in total assets and $100.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $72.10 (-0.09%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510018
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (5)Whales (4)SEC (3)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-18% Base Target
$163 Bull$59 Base$46 Bear
📬 FREE INBX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (18/100 Composite)
🔍 WHY INBX SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+5/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+4/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$87.08+9.4% Next Q
Q2 (-2Q)
23
Grade E$95.30+0.4% Next Q
Q3 (-1Q)
21
Grade E$95.66-24.6% Next Q
Current
18
Grade E$72.16-12.2% Hist 90D α
Trajectory: E (26) → E (18)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INBX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INBX currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($101.08) and Max Pain ($75.77) forces dealer call-delta covering toward $163.05.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INBX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INBX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INBX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INBX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INBX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBX)

  • ✓Walkthrough of INBX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INBX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.60%🛡️ HOLDING TREND SUPPORT
2026-11-03O $73.65H $73.65L $71.78C $72.16VOL 438.9K
RES: $163.4SUP: $65.37SMA50: $101.1SMA200: $92.15
$157.2$131.4$105.6$79.84$54.06RES $163.4SUP $65.37$72.162026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INBX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INBX Butterfly Map → + Track INBX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +550.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INBX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INBX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INBX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBX)

Health Care Rank #995 of 1015 ⚔️ IMTX vs INBX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INBX vs. IMTX, CGEM, VOR, ODTX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Inhibrx Biosciences Inc. (INBX) ranks #995 by composite RQD confidence (18/100, grade E) and #351 by equity capitalization ($1.06B). Within this direct 5-issuer industry benchmark cohort, INBX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with INBX at 18/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INBX ACTIVE
Inhibrx Biosciences Inc.
E 18/100 — — -35.0% +0.53% $1.06B Benchmark Subject
IMTX
Immatics N.V.
D 44/100 — — — -1.94% $1.08B /imtx-vs-inbx →
CGEM
Cullinan Therapeutics Inc.
E 32/100 — — -35.0% -0.66% $967.3M /cgem-vs-inbx →
VOR
Vor Biopharma Inc.
D- 42/100 — — -35.0% -2.18% $1.16B /vor-vs-inbx →
ODTX
Odyssey Therapeutics Inc.
D 46/100 — — — -0.05% $939.1M /odtx-vs-inbx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002007919 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inhibrx Biosciences Inc. (INBX) reported GAAP revenue of $1.3M (+550.0% vs. FY2024 revenue of $200.0K , and -27.8% cumulative change since FY2023) , GAAP net income of -$140.1M, operating cash flow of -$129.8M, and free cash flow of -$129.8M (+34.1% YoY). On the balance sheet, INBX closed FY2025 with $146.5M in total assets against $100.6M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.3M -$140.1M -$129.8M -$129.8M $146.5M $100.6M
FY2024 (FY) 2024-12-31 $200.0K $1.69B -$194.4M -$197.0M $180.8M $0
FY2023 (FY) 2023-12-31 $1.8M -$241.4M -$193.3M -$193.3M — —

3. INBX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Inhibrx Biosciences Inc. (NASDAQ: INBX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $72.16 (+0.53% 1D, market cap $1.06B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, INBX ranks #995 in composite RQD confidence.

How does INBX compare to IMTX and CGEM in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INBX carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $967.3M). Among the 5-stock peer group, INBX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INBX?

Per INBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002007919), Inhibrx Biosciences Inc. generated $1.3M in revenue (+550.0% YoY), -$140.1M in net income, and -$129.8M in free cash flow against $146.5M in total assets and $100.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INBX trading relative to its 50-day, 200-day, and 52-week technical levels?

INBX last traded at $72.16 (+0.53% on volume of 234,410 shares), positioning the stock -28.61% below its 50-day simple moving average ($101.08) and -21.69% below its 200-day simple moving average ($92.15). Across its 52-week range of $57.30 to $155.29, INBX sits at the 15.2% percentile with a 14-day RSI of 32.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($63.14 to $81.18).

Direct Sub-Reports: INBX RQD Cockpit INBX 12M Forecast INBX Earnings & Move INBX Dividends & DRIP INBX Insiders & 13F INBX Whale Options INBX Profit Sankey INBX News & Why
ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ SEC XBRL & RQD VERIFIED

INBX — Inhibrx Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Inhibrx Biosciences Inc. (INBX) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $72.16 (+0.53% 1D, market capitalization $1.06B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -11.98%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of 8.50x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Inhibrx Biosciences Inc. (INBX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Inhibrx Biosciences Inc. (INBX) reported $1.3M in annual revenue (up from $200.0K in FY2024, +550.0% YoY) and -$140.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.8M revenue, -$241.4M net income) through FY2025, INBX scaled operating cash flow to -$129.8M and free cash flow to -$129.8M, backed by $146.5M in total assets against $100.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 18/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.98% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $57.30 – $155.29 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the absence of mapped dependencies means second-order ripple effects cannot be assessed from the provided sources.

  • Key Question #1: Can INBX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.3M and free cash flow of -$129.8M, how will capital allocation balance growth reinvestment against $100.6M in total debt?
  • Key Question #3: How sensitive is INBX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INBX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Inhibrx Biosciences Inc. (INBX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INBX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INBX Bull vs. Bear Conversation Board — What's Your Call at $72.16?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INBX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INBX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $86.85 (+21.0%)
📌 Pinned Debate

A reported CEO purchase of over $848k in company stock and conference-data catalysts in the news flow.

A reported CEO purchase of over $848k in company stock and conference-data catalysts in the news flow.. When you look under the hood at INBX, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (4/20) has been quietly accumulating below $155.29. My 12M target is $86.85.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 4/20 institutional whale-flow stock at $71.78 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $56.71 (-21.0%)
Spot @ $71.78

An Altman Z-Score of 0.2, a Piotroski F-Score of 3/9, and ROIC of -35% alongside a Roarable RQD grade of E.

An Altman Z-Score of 0.2, a Piotroski F-Score of 3/9, and ROIC of -35% alongside a Roarable RQD grade of E.. Look at the math on INBX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $63.17 before getting long.

LIVE TAPE